Neurenati
Manufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
630 Boul. René-Lévesque O. Étage 20E, Mo...Website
www.neurenati.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Neurenati
Based in Montreal, Neurenati Therapeutics is a pioneering biotechnology company developing an innovative treatment for Hirschsprung's disease. Nicolas Pilon, expert in rare diseases, and Rodolphe Soret, specialist in neuro-gastroenterology, have combined their expertise to develop an innovative treatment for Hirschsprung's disease. With the additional support of serial entrepreneur Maxime Ranger and various experts in medicine, gastroenterology and clinical trials on rare diseases, the company is committed to bringing this treatment into clinical practice.Explore more
Neurenati Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neurenati your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Neurenati had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Neurenati has recently received funding, and reach out quickly before it becomes old news!
Check out if Neurenati is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Neurenati recently announced quarterly report
Product Launch: Get notified when Neurenati launches new products
Congratulate Masked Content for being promoted to Masked Content at Neurenati
Funding: Get notified immidiatlly once Neurenati has new funding data
Neurenati, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Neurenati as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Neurenati is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neurenati is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neurenati.
Neurenati financials insights
Gather financial insights about Neurenati, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Angel/Seed
$1.2M
Neurenati Tech Stack
A closer look at the technologies used by Neurenati
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Funding
Funding
Neurenati News & Media
The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease
MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics Inc., a biotech company focused on rare pediatric diseases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to NEU-001, a novel combination therapy utilizing a neurotrophic growth factor, for the treatment of Hirschsprung disease (HD). NEU-001 is a first-in-class, once-in-a-lifetime treatment administered intrarectally to regeneraNeurenati Therapeutics Strengthens Its Board of Directors With the Appointment of Dr. Marielle Cohard-Radice
MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics, a pediatric rare diseases-focused company, is delighted to announce the appointment of a highly-experienced executive in the pharma industry as an independent board member. Dr Marielle Cohard-Radice is a gastroenterologist who held various executive positions in several therapeutic areas over three decades. She is currently Executive Vice-president, Global Head of Development Operations at Daiichi Sankyo. “Marielle’s role will be key in refininNeurenati Therapeutics Closes Second Seed Financing of $1.7M
Neurenati Therapeutics, a Montreal, Québec, Canada-based biotech company dedicated to developing therapies for rare diseases, raised $1.38M in funding. Quebec Government made the investment via its Impulsion PME program. Angels participated in the second close. The company intends to use the funds to effectively advance NEU-001 toward clinical trials. Led by CEO and President Maxime […] The post Neurenati Therapeutics Closes Second Seed Financing of $1.7M appeared first on FinSMEs.Neurenati Therapeutics Concludes a Second Seed Financing of 1.7 Million $ With the Support of Impulsion PME
MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics is delighted to announce the Quebec Government’s investment of $1.38 million via its Impulsion PME program, for which Investissement Québec acts as agent. With the addition of angel investors, this brings the total funding to $2.9 million needed for Neurenati to effectively advance NEU-001 toward clinical trials. NEU-001 is a proposed first-in-class therapy to treat Hirschsprung's disease, a rare gastrointestinal disease affecting approximately
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Neurenati
Sign Up For FreeTo access detailed company insights
Based in Montreal, Neurenati Therapeutics is a pioneering biotechnology company developing an innovative treatment for Hirschsprung's disease. Nicolas Pilon, expert in rare diseases, and Rodolphe Soret, specialist in neuro-gastroenterology, have combined their expertise to develop an innovative treatment for Hirschsprung's disease. With the additio... Read More
